A Review of Introductal Papillary Mucinous Neoplasia Classification, Surgical Indications, and Outcomes
https://doi.org/10.16931/1995-5464.2025-3-63-69
Abstract
Intraductal papillary mucinous neoplasms (IPMNs) are pancreatic cystic lesions with malignant potential. This review outlines current guidelines, surgical indications, outcomes, and surveillance strategies. It also highlights recent advances in minimally invasive surgery and emerging biomarkers aimed at improving risk stratification and reducing unnecessary resections.
About the Authors
V. Dordevic
First Surgical Clinic, University Clinical Center of Serbia
Serbia
Serbia
Vladimir Đorđević – Doctor Specialist in General Surgery
11000 Belgrade
M. Markovic
First Surgical Clinic, University Clinical Center of Serbia
Serbia
Serbia
Marija Markovic – Medical Doctor
11000 Belgrade
M. Protić
University of Novi Sad, Faculty of Medicine; Oncology Institute of Vojvodina
Serbia
Serbia
Mlađan Protić – Head of Department of Abdominal Surgery; Professor at University
Novi Sad
Sremska Kamenica
Đ. Knežević
First Surgical Clinic, University Clinical Center of Serbia
Serbia
Serbia
Đorđe Knežević – Head of Department of General Surgery
11000 Belgrade
D. Basarić
First Surgical Clinic, University Clinical Center of Serbia
Serbia
Serbia
Dragan Basarić – Vice-head of Department of General Surgery
11000 Belgrade
S. Antovic
Medical Faculty Skopje, University Ss. Cyril and Methodius
Macedonia, the former Yugoslav Republic of
Macedonia, the former Yugoslav Republic of
Svetozar Antovic – Head of Department of General Surgery
Skopje
N. Grubor
First Surgical Clinic, University Clinical Center of Serbia
Serbia
Serbia
Nikica Grubor – Head of Department of General Surgery
11000 Belgrade
D. Radenković
First Surgical Clinic, University Clinical Center of Serbia
Serbia
Serbia
Dejan Radenković – Head of Department of General Surgery
11000 Belgrade
References
1. Abdalla T.S.A.A., Duhn J., Klinkhammer-Schalke M., et al. (2024). Oncological outcomes and patterns of recurrence after resection of invasive IPMN versus primary pancreatic adenocarcinoma: A multicenter analysis. Cancers, 16(13): 3400.
2. Addeo P., Canali G., Paul C., et al. (2024). Long-term survival after resection of invasive pancreatic intraductal papillary mucinous neoplasm. Langenbeck’s Arch Surg, 409(1): 361.
3. Crippa S., Bassi C., Salvia R., et al. (2017). Low progression of branch-duct IPMNs with worrisome features and high-risk stigmata under non-operative management: A mid-term follow-up analysis. Gut, 66(5): 862–869.
4. Davis C.H., Choubey A.P., Langan R.C., et al. (2024). Pancreatectomy for intraductal papillary mucinous neoplasm: Has anything changed in North America? HPB (Oxford), 26(1): 109–116.
5. Das K.K., Xiao H., Geng X., et al. (2014). mAb Das-1 is specific for high-risk and malignant intraductal papillary mucinous neoplasms of the pancreas. Gut, 63(10), 1626–1634.
6. Del Chiaro M., Besselink M.G., Scholten L., et al. (2018). European evidence-based guidelines on pancreatic cystic neoplasms. Gut, 67(5): 789–804.
7. Djordjevic V., Grubor N., Kovac J.D., et al. (2021). Comparison of preoperative evaluation with pathological report in intraductal papillary mucinous neoplasms: A single-center experience. Journal of Clinical Medicine, 10(4): 678.
8. Djordjevic V., Knezevic D., Trotovsek B., et al. (2024). Navigating IPMN management through Fukuoka consensus vs. European evidence-based guidelines on pancreatic cystic neoplasms – a study on two European centers. Cancers, 16(11): 2156. DOI: 10.3390/cancers16112156.
9. Elta G.H., Enestvedt B.K., Sauer B.G., Lennon A.M. (2018). ACG Clinical Guideline: Diagnosis and management of pancreatic cysts. American Journal of Gastroenterology, 113(4): 464–479.
10. Goh B.K.P., Tan D.M.Y., Thng C.H., et al. (2014). Are the Sendai and Fukuoka consensus guidelines for cystic mucinous neoplasms of the pancreas useful in the initial triage of all suspected pancreatic cystic neoplasms? A single-institution experience with 317 surgically-treated patients. Annals of Surgical Oncology, 21(6), 1919–1926
11. Leonhardt C.S., Hinz U., Kaiser J., et al. (2023). Presence of low-grade IPMN at the pancreatic transection margin does not have prognostic significance after resection of IPMN-associated carcinoma. European Journal of Surgical Oncology, 49(1): 113–121.
12. Marchegiani G., Mino-Kenudson M., Ferrone C.R., Morales-Oyarvide V., Warshaw A.L., Lillemoe K.D., Castillo C.F.-D. (2015). Patterns of recurrence after resection of IPMN: Who, when, and how? Annals of Surgery, 262(6), 1108–1114
13. Marchegiani G., Pollini T., Andrianello S., et al. (2023). Surveillance for presumed branch-duct IPMN of the pancreas: Stability, size, and age identify targets for discontinuation. Gastroenterology, 165(4): 1016–1024.e2.
14. Ohashi K., Murakami Y., Maruyama M., Takekoshi T., Ohta H., Ohashi I. (1982). Four cases of mucous-secreting pancreatic cancer. Progress in Digestive Endoscopy, 20, 348–351.
15. Ohtsuka T., Fernández-del Castillo C., Furukawa T., et al. (2024). International evidence-based Kyoto guidelines for the management of IPMN of the pancreas. Pancreatology, 24(2): 255–270.
16. Pergolini I., Sahora K., Ferrone C.R., et al. (2017). Long-term risk of pancreatic malignancy in patients with branch-duct IPMN after resection or observation. Gastroenterology, 153(5): 1284–1294.e1.
17. Roth S., Bose P., Alhamdani M.S.S., et al. (2021). Noninvasive discrimination of low and high-risk pancreatic intraductal papillary mucinous neoplasms. Annals of Surgery, 273(6): e273–e275.
18. Salahuddin A., Thayaparan V., Hamad A., et al. (2024). Recurrence following resection of intraductal papillary mucinous neoplasms: A systematic review to guide surveillance. Journal of Clinical Medicine, 13(3): 830.
19. Tanaka M., Castillo C.F.-D., Kamisawa T., et al. (2017). Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology, 17(5): 738–753. DO
20. Vege S.S., Ziring B., Jain R., Moayyedi P. (2015). American Gastroenterological Association Institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology, 148(4): 819–822.
21. Zhang C., Al-Shaheri F.N., Saiel M., et al. (2023). Blood-based diagnosis and risk stratification of patients with pancreatic IPMN. Clinical Cancer Research, 29(7): 1535–1545.
Review
For citations:
Dordevic V., Markovic M., Protić M., Knežević Đ., Basarić D., Antovic S., Grubor N., Radenković D. A Review of Introductal Papillary Mucinous Neoplasia Classification, Surgical Indications, and Outcomes. Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery. 2025;30(3):63-69. https://doi.org/10.16931/1995-5464.2025-3-63-69
Views:
17
Email this article 